Related references
Note: Only part of the references are listed.Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
Hsien-Yi Chiu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys
Jeffrey Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Effect of antie-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
Maha N. Syed et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Bruce E. Strober et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Management of pediatric plaque psoriasis using biologics
Perla Lansang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
Gerd R. Burmester et al.
ADVANCES IN THERAPY (2020)
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Anja Geldhof et al.
DRUG SAFETY (2020)
Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report
M. Venturini et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Desiree van der Heijde et al.
RHEUMATOLOGY (2020)
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong et al.
DERMATOLOGY AND THERAPY (2020)
Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
Lun-Fei Liu et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2020)
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
Jose Maria G. Ruiz de Morales et al.
AUTOIMMUNITY REVIEWS (2020)
Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden
Gabriella Broms et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
Akbar K. Waljee et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
Alice Gottlieb et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
A. S. Paller et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study
S. Philipp et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?
Matteo Megna et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans
James D. Chambers et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
COVID-19 and immunomodulator/immunosuppressant use in dermatology
Kyla N. Price et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
Marilyn T. Wan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Should biologics for psoriasis be interrupted in the era of COVID-19?
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
SARS-CoV-2 and COVID-19: The most important research questions
Kit-San Yuen et al.
CELL AND BIOSCIENCE (2020)
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
L. Puig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
Amy Kunchok et al.
JAMA NEUROLOGY (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Nicholas D. Brownstone et al.
DERMATOLOGY AND THERAPY (2020)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathwayeinhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
Maha N. Syed et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
May IL-17 have a role in COVID-19 infection?
Matteo Megna et al.
MEDICAL HYPOTHESES (2020)
One-Year Pharmacovigilance Update of Brodalumab
Mark Lebwohl et al.
Journal of Drugs in Dermatology (2020)
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Philip J. Mease et al.
RMD OPEN (2020)
EFFICACY OF TILDRAKIZUMAB IN PSA: DAS28-CRP SCORES THROUGH WEEK 52
S. Chohan et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
Alicja Goralczyk et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2020)
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab
Marco Galluzzo et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis
C. Leonardi et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient
Girum T. Assefa et al.
JOURNAL OF DERMATOLOGY (2019)
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study
Alexander Egeberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
Stephen Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2019)
Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis
C. Phan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives
Clara De Simone et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)
Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease
Joshua Korzenik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations
Stefano Piaserico et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions
Martin Diebold et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark G. Lebwohl et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Psoriatic arthritis: From pathogenesis to pharmacologic management
Rossella Talotta et al.
PHARMACOLOGICAL RESEARCH (2019)
Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study
Christina D. Chambers et al.
PLOS ONE (2019)
Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C
S. A. R. Siegel et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
Lieven Pouillon et al.
INFLAMMATORY BOWEL DISEASES (2019)
Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center
Zunirah Ahmed et al.
GASTROENTEROLOGY RESEARCH (2019)
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials
Jeffrey R. Curtis et al.
RMD OPEN (2019)
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials
Benedicte Champs et al.
RMD OPEN (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy of ustekinumab in biologic-naive patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
Iain B. McInnes et al.
RMD OPEN (2019)
Treatment strategies for psoriatic arthritis
Julien Schemoul et al.
JOINT BONE SPINE (2018)
Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study
Vito Di Lernia et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study
Hsien-Yi Chiu et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab
Sze-Wen Ting et al.
CLINICAL DRUG INVESTIGATION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
J. W. Baddley et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
Florenzo Iannone et al.
CLINICAL RHEUMATOLOGY (2018)
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Zenas Z. N. Yiu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Scott M. Whitlock et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT)
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Pediatric psoriasis: Evolving perspectives
Lawrence F. Eichenfield et al.
PEDIATRIC DERMATOLOGY (2018)
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1)
Alice B. Gottlieb et al.
RHEUMATOLOGY (2018)
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Mark C. Genovese et al.
RHEUMATOLOGY (2018)
Pregnancy Outcomes After Exposure to Certolizumab Pegol Updated Results From a Pharmacovigilance Safety Database
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Psoriasis, Cardiovascular events, and Biologics: Lights and Shadows
Giuseppina Caiazzo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
Paul Rutgeerts et al.
GASTROENTEROLOGY (2018)
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Mina Amin et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration
Marius Rademaker et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2018)
OVERALL SAFETY OF 7-WEEK SECUKINUMAB EXPOSURE DURING PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS
M. Meroni et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Philip J. Mease et al.
RMD OPEN (2018)
Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol
Alina Soare et al.
CLINICAL RHEUMATOLOGY (2018)
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience
Pablo Olivera et al.
INFLAMMATORY BOWEL DISEASES (2017)
Old and New Biological Therapies for Psoriasis
Kirsten Ronholt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Ixekizumab and pregnancy outcome
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Igor Snast et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population
Maryam M. Asgari et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriasis and multiple sclerosis - hidden link?
U. Gieler
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial
Kim Papp et al.
LANCET (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2017)
Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
Zheng Zhang et al.
BMJ OPEN (2017)
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
Megan E. B. Clowse et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter et al.
DERMATOLOGY AND THERAPY (2017)
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
Michael Kammueller et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2017)
The global state of psoriasis disease epidemiology: a workshop report
C. E. M. Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
C. E. M. Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
Salvatore D'Angelo et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2017)
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
L. Dreyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA
Aoibhlinn O'Toole et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Just in Time: When Is It Safe to Administer Live Vaccines to Infants Exposed to Anti-Tumor Necrosis Factor Agents In Utero?
Cynthia H. Seow et al.
GASTROENTEROLOGY (2016)
Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study
Alexander Egeberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
Eva Havrdova et al.
JOURNAL OF NEUROLOGY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Risk of Cancer in Patients With Psoriasis A Population-Based Cohort Study in the Health Improvement Network
Zelma C. Chiesa Fuxench et al.
JAMA DERMATOLOGY (2016)
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Fabrizio Cantini et al.
AUTOIMMUNITY REVIEWS (2015)
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
S. C. Heslinga et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Pregnancy during Ustekinumab Treatment for Severe Psoriasis
Katiucia Rocha et al.
DERMATOLOGY (2015)
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ian Landells et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations
Shunsuke Mori et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Psoriasis and risk of heart failure: a nationwide cohort study
Usman Khalid et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis
Kiran Motaparthi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
Jeremy Hugh et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Management of chronic hepatitis B in severe liver disease
James Fung et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
Pawel Kawalec et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
H. -Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies
C. Pouplard et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey
Raphaele Seror et al.
RHEUMATOLOGY (2013)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study
Meng-Sui Lee et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis
Maria A. Lopez-Olivo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy
L. Puig
ACTAS DERMO-SIFILIOGRAFICAS (2012)
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials
Erica D. Dommasch et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Johan Askling et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-α–Blocker Therapy
Pierre Lozeron et al.
ARCHIVES OF NEUROLOGY (2009)
Inflammatory demyelinating events following treatment with anti-tumor necrosis factor
A. Fromont et al.
CYTOKINE (2009)
Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case-Control Analysis
Yolanda B. Brauchli et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Screening for tuberculosis infection prior to initiation of anti-TNF therapy
Ajit Lalvani et al.
AUTOIMMUNITY REVIEWS (2008)
Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study
Nynne Nyboe Andersen et al.
JOURNAL OF CROHNS & COLITIS (2008)
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents
Sean D. Doherty et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Repeated subcutaneous injections of IL12/23 P40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Benjamin M. Segal et al.
LANCET NEUROLOGY (2008)
Etanercept treatment for children and adolescents with plaque psoriasis
Amy S. Paller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
The risk of lymphoma in patients with psoriasis
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Problems encountered during anti-tumour necrosis factor therapy
Sheetal B. Desai et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
HJ Kwon et al.
ANNALS OF INTERNAL MEDICINE (2003)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
